Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	29.79	33.51	25.18	44.35	30.36	15.37
Short-Term Investments	7.57	0	0	2.5	48.99	61.5
Cash & Cash Equivalents	37.35	33.51	25.18	46.85	79.35	76.87
Cash Growth	361.19%	33.10%	-46.27%	-40.96%	3.24%	-36.04%
Receivables	21.53	21.56	17.14	1.82	3.31	15
Inventory	4.94	4.28	6.12	0	0	0
Other Current Assets	-1.09	-2.13	1.22	2.81	6.84	4.2
Total Current Assets	62.72	57.22	49.65	51.48	89.51	96.07
Property, Plant & Equipment	23.92	23.78	18.38	3.71	2.27	2.23
Long-Term Investments	23.11	23.43	7.39	0	2.54	0
Goodwill and Intangibles	1.68	1.7	1.86	0	0	0
Other Long-Term Assets	10.58	10.41	7.48	0.47	0.53	0.26
Total Long-Term Assets	59.29	59.32	35.1	4.19	5.34	2.49
Total Assets	122.01	116.54	84.75	55.66	94.85	98.55
Accounts Payable	1.69	1.72	0.24	6.42	5.93	4.28
Deferred Revenue	0.24	0.25	0.26	0.23	1.98	15
Current Debt	0.1	0.21	0.49	1.98	0.66	0.48
Other Current Liabilities	17.46	17.86	11.25	5.54	9.22	9.14
Total Current Liabilities	19.49	20.05	12.24	14.17	17.8	28.9
Long-Term Debt	0.18	0.2	0.12	0.41	0.98	1.32
Other Long-Term Liabilities	13.58	17.82	0.17	0	0	0
Total Long-Term Liabilities	13.75	18.02	0.29	0.41	0.98	1.32
Total Liabilities	33.24	38.07	12.54	14.57	18.78	30.22
Total Debt	0.28	0.41	0.61	2.39	1.64	1.8
Debt Growth	-	-33.28%	-74.30%	45.07%	-8.77%	-
Retained Earnings	-78.01	-85.54	7.4	-402.69	-314.76	-258.52
Comprehensive Income	-1.74	-1.64	-0.39	0	0.01	0.03
Shareholders' Equity	56.64	-15.83	42.52	41.09	76.07	68.34
Net Cash / Debt	37.08	33.1	24.56	44.47	77.71	75.06
Net Cash / Debt Growth	357.80%	34.76%	-44.76%	-42.78%	3.53%	-37.54%
Net Cash Per Share	0.36	0.50	0.32	21.77	60.78	93.79
Working Capital	43.24	37.17	37.41	37.31	71.71	67.17
Book Value Per Share	0.68	-0.24	0.67	20.11	59.49	85.39

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).